Ultragenyx Pharma (RARE) Reports Q4 Loss of $0.37 on Revenues of $91.54M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
UPDATE: Ultragenyx Pharma (RARE) Sees Intra-Day Weakness
February 10, 2021 10:38 AM EST(Updated - February 10, 2021 10:43 AM EST)
Ultragenyx Pharma (NASDAQ: RARE) sees mid-day weakness, shares down 1.7%.
UPDATE: Weakness said related to FDA FAERS database showing Dojolvi drug has lead to several recent deaths.
... More